100 Clinical Results associated with Amide Biomedical Technology (Tianjin) Co., Ltd.
0 Patents (Medical) associated with Amide Biomedical Technology (Tianjin) Co., Ltd.
Amide Technologies is now marketing its peptide manufacturing technology at a time when peptide-based therapies such as Novo Nordisk’s Wegovy and Eli Lilly’s Mounjaro are in high demand.
The Cambridge, MA startup, which was spun out of the Massachusetts Institute of Technology in 2016, developed a technology that more quickly synthesizes long chains of amino acids into peptides.
CEO Mark Simon said in an interview with
Endpoints
News
that Amide’s tech could help ease the supply crunch for GLP-1 drugs because the company manufactures peptides faster than traditional methods.
Lilly
and
Novo
have both reported several manufacturing roadblocks trying to meet the demand for their GLP-1 drugs.
100 Deals associated with Amide Biomedical Technology (Tianjin) Co., Ltd.
100 Translational Medicine associated with Amide Biomedical Technology (Tianjin) Co., Ltd.